Evans John M. sold $1.2M of BEAM

Evans John M. (CEO) sold 50,000 shares of Beam Therapeutics Inc. (BEAM) at an average of $23.77 ($23.57–$23.98, $1.19M total) across 2 trades over 2026-10-15 to 2026-10-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Evans John M.
Published Oct 17, 2026, 12:09 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 17, 2026, 12:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BEAM
Bearish
high confidence
Mentioned
$BEAM
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BEAMBearishLow
01

Why it matters

The disclosed sale reduces the CEO's ownership and may be interpreted by the market as a lack of confidence, prompting short‑term price weakness.

02

Market read

Primary insider sale news; modest materiality for traders monitoring biotech stocks and insider activity.

03

What to watch

Potential upcoming clinical data releases could offset the sell‑off if positive.

Relevance 5/10Novelty 6/10Timing: after-hours on filing day

Background

Form 4 filings provide transparent disclosure of insider transactions. BEAM is a CRISPR‑based gene‑editing company listed on NASDAQ.

Company-level read

Ticker impact

$BEAMBearishHigh confidence
Context

CEO Evans John M. sold 50,000 shares for $1.19M via a 10b5‑1 plan, reducing his stake to 1,047,205 shares.

Expected impact

likely downward pressure as the market prices the CEO's sell-off

Evidence & confidence

Form 4 filings are primary disclosures; a $1.2M sale by the CEO is material for a mid‑cap biotech and often triggers short‑term selling.

Market effects

May raise caution for biotech sector investors tracking insider activity.

Limited to U.S. biotech investors; no broader regional effect.

Minimal global impact; relevant primarily to BEAM shareholders.

Counterpoint

The sale could be routine under a pre‑arranged 10b5‑1 plan and not reflect negative outlook.

Key entities

  • Beam Therapeutics Inc.

    NASDAQ‑listed biotech focused on gene editing.

  • Evans John M.

    CEO of Beam Therapeutics, insider seller.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BEAMHighAI 9/10

Beam Sickle Cell Therapy Meets Pivotal Goals

Beam Therapeutics reported positive pivotal trial results for risto-cel, its sickle cell treatment, meeting all primary and secondary endpoints. The trial showed patients stayed free of severe vaso-occlusive crises for at least 12 months. Beam plans to file for FDA approval by year-end 2026, aiming to be the first base-editing therapy approved in the US. The company will present detailed results at a medical meeting in 2027.